Long-term effects of pentoxifylline in heart failure therapy

Authors : Ahmet KARAGÖZ, Özgül UÇAR, Ayşe YÜKSEL, Sinan AYDOĞDU

Pages : 19-23

View : 43 | Download : 13

Publication Date : 2014-06-05

Article Type : Research Paper

Abstract :The aim of the present study is to investigate the effects of pentoxifylline on left ventricular ejection fractions insert ignore into journalissuearticles values(EF); and volumes, New York Heart Association insert ignore into journalissuearticles values(NYHA); functional class, left ventricular diastolic parameters and hospitalization for heart failure in patients with ischemic or non-ischemic cardiomyopathy. A total of 60 patients were randomised to either peroral 1200 mg/day pentoxifylline or control group. All patients were on optimal heart failure therapy and their EF was <40% by transthoracic echocardiography. The patients were followed up for 12 months. Twenty-one patients insert ignore into journalissuearticles values(70%); in pentoxifylline group and 20 insert ignore into journalissuearticles values(66.7%); in control group completed the study. Baseline and 12 months’ end-diastolic volume, end-systolic volume, EF and NYHA class were as follows in pentoxifylline group; 160.5±51.3 mL vs 156.6±43.1 mL, 109.1±40 mL vs 106.1±33.4 mL, 32.4±5.7% vs 33.2±5.2%, 2.4±0.5 vs 2.2±0.5, p=0.5411, 0.5257, 0.4099 and 0.1037; respectively. There were also no difference in baseline and follow-up diastolic parameters. Mean hospitalization numbers for heart failure were similar between groups insert ignore into journalissuearticles values(1.26±0.71 vs 1.60±1.04, p=0.1717);. Contrary to previous reports, no beneficial effect of pentoxifylline was observed on clinical or echocardiographic parameters.
Keywords : Echocardiography, Heart failure, Pentoxifylline, Therapy

ORIGINAL ARTICLE URL